Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is expected to release its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.78) per share and revenue of $0.4310 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The business had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. On average, analysts expect Upstream Bio to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Upstream Bio Stock Performance

Shares of UPB opened at $6.40 on Wednesday. The stock has a market capitalization of $348.29 million, a PE ratio of -2.20 and a beta of 1.23. Upstream Bio has a 1 year low of $5.85 and a 1 year high of $33.68. The company’s 50-day simple moving average is $7.11 and its 200-day simple moving average is $11.96.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. downgraded shares of Upstream Bio from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $35.00 to $8.00 in a research note on Friday, June 12th. HC Wainwright began coverage on shares of Upstream Bio in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price target for the company. Mizuho dropped their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 14th. Finally, Weiss Ratings lowered Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $33.17.

Institutional Investors Weigh In On Upstream Bio

Several institutional investors have recently added to or reduced their stakes in the business. Empowered Funds LLC acquired a new position in Upstream Bio in the fourth quarter valued at approximately $45,000. Russell Investments Group Ltd. raised its stake in Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after acquiring an additional 2,887 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares during the last quarter. Legal & General Group Plc boosted its stake in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after acquiring an additional 1,440 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in Upstream Bio in the fourth quarter valued at $242,000.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.